"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 3 | 5 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 4 | 4 | 8 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 4 | 4 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2023 Apr 13; 24(8).
-
The incidence and characteristics of VTE within 100?days of CAR T-cell therapy. Ann Hematol. 2023 03; 102(3):683-685.
-
Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy. Ann Hematol. 2023 02; 102(2):461-462.
-
Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):e14-e18.
-
Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 09; 28(9):583-585.
-
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Adv. 2022 06 14; 6(11):3398-3403.
-
Review of Hematological and Oncological Emergencies. Adv Emerg Nurs J. 2022 Apr-Jun 01; 44(2):84-102.
-
B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
-
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):326-335.
-
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-d and -?. Front Immunol. 2021; 12:718621.